Pharma BD Deal Intelligence
Engitix gains access to Lonza's GlycoConnect, HydraSpace and SYNtecan E technologies to build an ADC against an ECM target.
Lonza and Engitix announce a single-target license to Lonza's ADC platform (SYNtecan E, GlycoConnect, HydraSpace); Lonza eligible for upfront, milestone and…
Source summaries from our enrichment pipeline; follow links for originals.
All 3 sources with sentiment breakdown →
Engitix Therapeutics took a single-target license to Lonza's antibody-drug conjugate technology platform, announced July 21, 2026, to develop an ADC directed at a target identified through Engitix's proprietary extracellular-matrix (ECM) discovery platform. The license covers Lonza's SYNtecan E linker-payload plus its complementary GlycoConnect and HydraSpace site-specific conjugation technologies. Lonza is eligible for undisclosed upfront, clinical, regulatory and commercial milestone payments plus royalties, and will manufacture components tied to its proprietary technologies; Engitix is responsible for research, development, manufacturing and commercialization of the resulting ADCs. Financial terms were not disclosed.
← Browse all deals · How we score deals
More: 2026 deals